ImmunoplexTM enables needle-free, infectious agent-free immune complex vaccines, as well as autologous cellular oncology vaccines.
ImmunoplexTM is a platform technology aimed at transforming the $26B global vaccine market by delivering cost effective needle-free immune complex vaccines without side effects. The crux of the invention includes a proprietary tag and an antibody that create immune complexes in a universal fashion. Proof of concept has been achieved in HepB, influenza, and breast cancer. Memcine will function as a discovery engine for the pharma industry.
Kathleen Holt, PhD, CEO, has over 14 years’ executive level experience forging collaborations for the advancement of scientific discovery and translation into high impact deliverables. Dr. Holt has directed business development for multiple startup companies including Lexicon Pharma, and KemPharm. Dr. Holt holds a BS degree in Biology from the SUNY, and a PhD in Molecular Biology from The University of Iowa College of Medicine.
Tony Vanden Bush, PhD, Co-inventor, Director, and Chief Scientific Officer, is a research scientist in the University of Iowa Department of Microbiology. Dr. Vanden Bush also serves on the scientific advisory board for Memcine. Dr. Vanden Bush has an undergraduate degree in Biochemistry/Molecular Biology from University of Wisconsin, Eau Claire, and a PhD with honors in Immunobiology and Biochemistry from Iowa State University.
Gregory M. Landes, PhD, currently serves as a consultant for the global biotherapeutics industry at DNA Bridges, Inc. Dr. Landes has prior executive experience with numerous biopharmaceutical companies including: Takeda, Lexicon Pharma, Abgenix, and Genzyme. Dr. Landes holds 16 issued US patents pertaining to antibody drugs. Dr. Landes earned his PhD in Biochemistry from the University of Kansas and received postdoctoral training at UCLA.